- Home
- GVH vs BIVI Comparison
GVH vs BIVI Comparison
Compare GVH & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GVH
- BIVI
- Stock Information
- Founded
- GVH 2016
- BIVI 2013
- Country
- GVH Australia
- BIVI United States
- Employees
- GVH N/A
- BIVI N/A
- Industry
- GVH
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- GVH
- BIVI Health Care
- Exchange
- GVH Nasdaq
- BIVI Nasdaq
- Market Cap
- GVH 22.8M
- BIVI 18.6M
- IPO Year
- GVH 2023
- BIVI N/A
- Fundamental
- Price
- GVH $1.37
- BIVI $1.08
- Analyst Decision
- GVH
- BIVI Strong Buy
- Analyst Count
- GVH 0
- BIVI 1
- Target Price
- GVH N/A
- BIVI $30.00
- AVG Volume (30 Days)
- GVH 99.9K
- BIVI 282.1K
- Earning Date
- GVH 02-12-2025
- BIVI 05-12-2025
- Dividend Yield
- GVH N/A
- BIVI N/A
- EPS Growth
- GVH 12.04
- BIVI N/A
- EPS
- GVH 0.09
- BIVI N/A
- Revenue
- GVH $16,540,178.00
- BIVI N/A
- Revenue This Year
- GVH N/A
- BIVI N/A
- Revenue Next Year
- GVH N/A
- BIVI N/A
- P/E Ratio
- GVH $14.79
- BIVI N/A
- Revenue Growth
- GVH N/A
- BIVI N/A
- 52 Week Low
- GVH $0.47
- BIVI $0.62
- 52 Week High
- GVH $1.82
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- GVH 57.93
- BIVI 53.42
- Support Level
- GVH $1.33
- BIVI $1.07
- Resistance Level
- GVH $1.45
- BIVI $1.13
- Average True Range (ATR)
- GVH 0.15
- BIVI 0.06
- MACD
- GVH -0.05
- BIVI 0.00
- Stochastic Oscillator
- GVH 11.76
- BIVI 65.99
About GVH Globavend Holdings Limited
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.